1-20 of 30
John J. Wright
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Roisin M. Connolly, Victoria Wang, David M. Hyman, Petros Grivas, Edith P. Mitchell, John J. Wright, Elad Sharon, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jue Wang, Kari B. Wisinski, James V. Tricoli, Barbara A. Conley, Lyndsay N. Harris, Carlos L. Arteaga, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1273–1280.
https://doi.org/10.1158/1078-0432.CCR-23-0633
Published: 01 April 2024
View article titled, Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
Open the PDF for Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J in another window
Includes: Supplementary data
Journal Articles

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Daniel M. Girardi, Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal, Biren Saraiya, Lisa Cordes, Lisa Ley, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Diaz, Hadi Bagheri, Bernadette Redd, Seth M. Steinberg, Rene Costello, Keith S. Chan, Min-Jung Lee, Sunmin Lee, Yunkai Yu, Sandeep Gurram, Heather J. Chalfin, Vladimir Valera, William D. Figg, Maria Merino, Antoun Toubaji, Howard Streicher, John J. Wright, Elad Sharon, Howard L. Parnes, Yang-Min Ning, Donald P. Bottaro, Liang Cao, Jane B. Trepel, Andrea B. Apolo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1353–1362.
https://doi.org/10.1158/1078-0432.CCR-21-3726
Published: 01 April 2022
View article titled, Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Open the PDF for Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy in another window
Includes: Supplementary data
Journal Articles

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Lawrence Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald Bottaro, Rene Costello, John J. Wright, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 279–288.
https://doi.org/10.1158/1078-0432.CCR-21-2480
Published: 15 January 2022
View article titled, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Open the PDF for Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak, Yen-Lin Chu, Robin Richardson, Rachel Krupa, Amanda K.L. Anderson, Yipeng Wang, Ryan Dittamore, Sumanta K. Pal, Primo N. Lara, Mark N. Stein, David I. Quinn, Seth M. Steinberg, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Rene Costello, Jacqueline Cadena, Carlos Diaz, James L. Gulley, William L. Dahut, Howard Streicher, John J. Wright, Jane B. Trepel, Donald P. Bottaro, Andrea B. Apolo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1391–1398.
https://doi.org/10.1158/1078-0432.CCR-20-2891
Published: 01 March 2021
View article titled, Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
Open the PDF for Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean Hurteau, Koji Matsuo, Daniela Matei, Waldo Jimenez, Carolyn Johnston, Mihaela Cristea, Katia Tonkin, Prafull Ghatage, Stephanie Lheureux, Anjali Mehta, Judy Quintos, Qian Tan, Suzanne Kamel-Reid, Olga Ludkovski, Ming-Sound Tsao, John J. Wright, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2477–2486.
https://doi.org/10.1158/1078-0432.CCR-19-2576
Published: 01 June 2020
View article titled, Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Open the PDF for Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86) in another window
Includes: Supplementary data
Journal Articles

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Douglas B. Johnson, Fengmin Zhao, Marcus Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Shuli Li, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanly R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1812–1819.
https://doi.org/10.1158/1078-0432.CCR-19-3443
Published: 15 April 2020
View article titled, Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Open the PDF for Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) in another window
Includes: Supplementary data
Journal Articles

Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M. Greer, L. Austin Doyle, John J. Wright, Judith E. Karp, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3592–3600.
https://doi.org/10.1158/1078-0432.CCR-16-2629
Published: 13 July 2017
View article titled, Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Open the PDF for Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent

Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, Christine Bryla, Christophe E. Redon, Asako J. Nakamura, William M. Bonner, John J. Wright, Richard Piekarz, David R. Kohler, Yixing Jiang, Chandra P. Belani, Julie Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 721–729.
https://doi.org/10.1158/1078-0432.CCR-14-1333
Published: 16 February 2015
View article titled, A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Open the PDF for A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Victor G. Prieto, Kirk S. Culotta, Timothy L. Madden, Quanyun Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet E. Dancey, John J. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1120–1128.
https://doi.org/10.1158/1078-0432.CCR-11-2436
Published: 14 February 2012
View article titled, Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Open the PDF for Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

Athanassios Argiris, Austin G. Duffy, Shivaani Kummar, Nicole L. Simone, Yoshio Arai, Seungwon W. Kim, Susan F. Rudy, Vishnu R. Kannabiran, Xinping Yang, Minyoung Jang, Zhong Chen, Nanette Suksta, Theresa Cooley-Zgela, Susmita G. Ramanand, Aarif Ahsan, Mukesh K. Nyati, John J. Wright, Carter Van Waes
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5755–5764.
https://doi.org/10.1158/1078-0432.CCR-11-0861
Published: 01 September 2011
View article titled, Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
Open the PDF for Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, Peter Choyke, Baris Turkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1190–1199.
https://doi.org/10.1158/1078-0432.CCR-10-2331
Published: 01 March 2011
View article titled, Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
Open the PDF for Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

Jeffrey E. Lancet, Vu H. Duong, Elliott F. Winton, Robert K. Stuart, Michelle Burton, Shumin Zhang, Christopher Cubitt, Michelle A. Blaskovich, John J. Wright, Said Sebti, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1140–1146.
https://doi.org/10.1158/1078-0432.CCR-10-1878
Published: 01 March 2011
View article titled, A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias
Open the PDF for A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias in another window
Journal Articles

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

John J. Wright
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (16): 4094–4104.
https://doi.org/10.1158/1078-0432.CCR-09-2882
Published: 11 August 2010
View article titled, Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
Open the PDF for Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

David S. Hong, Said M. Sebti, Robert A. Newman, Michelle A. Blaskovich, Lei Ye, Robert F. Gagel, Stacy Moulder, Jennifer J. Wheler, Aung Naing, Nizar M. Tannir, Chaan S. Ng, Steven I. Sherman, Adel K. El Naggar, Rabia Khan, Jon Trent, John J. Wright, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7061–7068.
https://doi.org/10.1158/1078-0432.CCR-09-1241
Published: 11 November 2009
View article titled, Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
Open the PDF for Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies in another window
Journal Articles

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

Ashraf Badros, Angelika M. Burger, Sunita Philip, Ruben Niesvizky, Sarah S. Kolla, Olga Goloubeva, Carolynn Harris, James Zwiebel, John J. Wright, Igor Espinoza-Delgado, Maria R. Baer, Julianne L. Holleran, Merrill J. Egorin, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5250–5257.
https://doi.org/10.1158/1078-0432.CCR-08-2850
Published: 12 August 2009
View article titled, Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Open the PDF for Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma in another window
Journal Articles

Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer

Joseph A. Sparano, Stacy Moulder, Aslamuzzaman Kazi, Domenico Coppola, Abdissa Negassa, Linda Vahdat, Tianhong Li, Christine Pellegrino, Susan Fineberg, Pam Munster, Mokenge Malafa, David Lee, Shira Hoschander, Una Hopkins, Dawn Hershman, John J. Wright, Celina Kleer, Sofia Merajver, Said M. Sebti
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (8): 2942–2948.
https://doi.org/10.1158/1078-0432.CCR-08-2658
Published: 15 April 2009
View article titled, Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer
Open the PDF for Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer in another window
Journal Articles

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

Judith E. Karp, B. Douglas Smith, Ivana Gojo, Jeffrey E. Lancet, Jacqueline Greer, Maureen Klein, Larry Morris, Mark J. Levis, Steven D. Gore, John J. Wright, Elizabeth Garrett-Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3077–3082.
https://doi.org/10.1158/1078-0432.CCR-07-4743
Published: 15 May 2008
View article titled, Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Open the PDF for Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features in another window
Journal Articles

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

Virginia M. Klimek, Sophia Fircanis, Peter Maslak, Ilhem Guernah, Michael Baum, Nian Wu, Katherine Panageas, John J. Wright, Pier Paolo Pandolfi, Stephen D. Nimer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 826–832.
https://doi.org/10.1158/1078-0432.CCR-07-0318
Published: 01 February 2008
View article titled, Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
Open the PDF for Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes in another window
Journal Articles

Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

Razelle Kurzrock, Hagop M. Kantarjian, Michelle A. Blascovich, Cindy Bucher, Srdan Verstovsek, John J. Wright, Susan R. Pilat, Jorge E. Cortes, Elihu H. Estey, Francis J. Giles, Miloslav Beran, Said M. Sebti
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 509–514.
https://doi.org/10.1158/1078-0432.CCR-07-1532
Published: 25 January 2008
View article titled, Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Open the PDF for Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome in another window
Journal Articles

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

David S. Schrump, Maria R. Fischette, Dao M. Nguyen, Ming Zhao, Xinmin Li, Tricia F. Kunst, Ana Hancox, Julie A. Hong, G. Aaron Chen, Evgeny Kruchin, John J. Wright, Douglas R. Rosing, Alex Sparreboom, William D. Figg, Seth M. Steinberg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (1): 188–198.
https://doi.org/10.1158/1078-0432.CCR-07-0135
Published: 02 January 2008
View article titled, Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Open the PDF for Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin in another window